Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | EBP | Q15125 | 1/20 | 0.33 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26242517 | 0.89 | NPC1 (0.48) | RAB9ANPC1HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL26254400 | 0.84 | ACHE (0.41) | RAB9ANPC1MEN1KMT2AKDM4E | |
| SCHEMBL13818481 | 0.84 | ACHE (0.41) | RAB9ANPC1MEN1KMT2AKDM4E | |
| SCHEMBL4521726 | 0.81 | SMN1; SMN2 (0.39) | RAB9ANPC1HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL21613806 | 0.80 | DHCR7 (0.50) | RAB9ANPC1HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL21613729 | 0.77 | DHCR7 (0.56) | RAB9ANPC1HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL22572824 | 0.76 | USP2 (0.46) | HPGDSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL25650180 | 0.73 | HRH3 (0.32) | RAB9ANPC1HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL18583232 | 0.72 | HPGD (0.43) | RAB9ANPC1HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL18583327 | 0.72 | USP2 (0.37) | ALDH1A1LMNAHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156831-A1 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | MERLI VALERIANO | 2009-06-18 | — | — | US | disclosed |
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | CHRNE, CHRM3, CHRM2 | RAB9A 3273/4885NPC1 4762/4885HPGD 362/4885 |
| US-20090156831-A1 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | OPRL1, AVPR2, AVPR1B | RAB9A 956/4885NPC1 4114/4885HPGD 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.